Prior Scientific Competitors

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling almost 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets (September 30, 2025). For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses, and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare, and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 46,600 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 30 production facilities worldwide. Learn more about ZEISS: www.zeiss.com/about Data privacy: www.zeiss.com/data-protection Imprint: www.zeiss.com/publisher This is ZEISS's official LinkedIn account. It follows the ZEISS Netiquette: www.zeiss.com/netiquette

Olympus is passionate about creating customer-driven solutions for the medical industry. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 31,000 employees worldwide in nearly 40 countries and regions.

Leica Biosystems is proud to be part of Danaher. Danaher’s science and technology leadership puts Leica Biosystems’ solutions at the forefront of the industry, so they can reachmore people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions toour customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformativepotential of cutting-edge science and technology to improvebillions of lives every day. -- Leica Biosystems Privacy Policy can be found at: https://www.leicabiosystems.com/about/privacy-policy/ The collection, storage, use, disclosure, retention and destruction of data on this page, including any personal data, are all subject, as applicable, to Leica Biosystems’ Terms of Use and Privacy Policy. We do not endorse or approve user generated content to promote any other use of our products and will remove any comments or references to such off-label use. We reserve the right to remove a topic or comment at our discretion. By accessing the content, you expressly acknowledge and agree: (1) the content is provided only as a convenience to you and you are accessing the content for your personal educational purposes only; (2) the content may be from a variety of sources over which Leica Biosystems has no control, and should therefore not be interpreted as representing the opinions of, or an endorsement by, Leica Biosystems or its associates; (3) the content is provided to you AS IS, and you release Leica Biosystems of any responsibility or damages you may suffer as a result of the content, including without limitation, any damages resulting from the inaccuracy or unsuitability of the content.